Wall Street Zen Downgrades Context Therapeutics (NASDAQ:CNTX) to Sell

Context Therapeutics (NASDAQ:CNTX) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

CNTX has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, January 21st. HC Wainwright lifted their price objective on Context Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. JonesTrading began coverage on Context Therapeutics in a research report on Monday, December 22nd. They issued a “buy” rating and a $7.00 target price for the company. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a report on Thursday, November 6th. Finally, Lifesci Capital raised shares of Context Therapeutics to a “strong-buy” rating in a research note on Monday, February 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Context Therapeutics has an average rating of “Moderate Buy” and an average price target of $6.00.

Context Therapeutics Trading Down 1.3%

Shares of Context Therapeutics stock opened at $2.25 on Friday. Context Therapeutics has a 1 year low of $0.49 and a 1 year high of $2.85. The company’s fifty day simple moving average is $1.90 and its 200-day simple moving average is $1.34. The company has a market cap of $206.73 million, a price-to-earnings ratio of -9.38 and a beta of 1.94.

Hedge Funds Weigh In On Context Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Clear Harbor Asset Management LLC raised its holdings in shares of Context Therapeutics by 60.5% in the third quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after buying an additional 35,000 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Context Therapeutics by 4.0% during the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after purchasing an additional 134,449 shares in the last quarter. Citadel Advisors LLC bought a new stake in shares of Context Therapeutics during the third quarter valued at approximately $100,000. Blue Owl Capital Holdings LP raised its position in Context Therapeutics by 0.3% in the 4th quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock worth $10,926,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Context Therapeutics by 58.8% during the 4th quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock worth $747,000 after buying an additional 188,202 shares in the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.